Rousselot, Darling Ingredients’ premier collagen and gelatin brand, will announce the results of the first clinical study behind the company’s latest innovation, Nextida GC. Unveiled earlier this year, the solution is the first ingredient commercialized from the Nextida platform, a range of specific collagen peptide compositions with targeted health benefits to support the body’s balance, naturally.
The trial showed that both a 5- and 10-gram dose of Nextida GC significantly lowered post-meal glucose spikes in healthy individuals when taken orally 30 minutes before a meal, reducing the glucose spike in the blood by 42% on average after the meal.(1)
“We’re immensely excited to take our new step toward decoding the collagen molecule with the release of this first study,” said Jeroen Colpaert, Executive Vice President, Rousselot. “With new science supporting our ingredient’s potential for post-meal glucose metabolism in healthy individuals, we are continuing our commitment to offering the health and wellness industry evidence-based solutions that expand what we know about collagen.”
As the event’s official sponsor for glucose management, Rousselot will also be delivering two expert presentations which aim to shed light on this increasingly hot topic. Dr. Janne Prawitt, Scientific Director Health & Nutrition at Rousselot, and Dr. Mariette Abrahams, CEO & Founder at Qina, will discuss the consumer-led metabolic revolution surrounding Nextida GC on Wednesday, Oct. 30, at 12 p.m. – 1 p.m. PST, Lower Level, South Pacific Ballroom D. On Thursday, Oct. 31, at 11 a.m. – 11:20 a.m. PST, at the Supplier Presentation Theater, Dr. Prawitt will provide insights into Nextida GC’s first clinical trial.
Show attendees can connect with Rousselot at booth 5641, to sample Nextida GC and learn more about two recently published, peer-reviewed clinical studies concerning Rousselot's flagship collagen peptide solution Peptan®. One highlights its efficacy in enhancing skin beauty markers,(2) while another demonstrates its effective absorption(3), with both reinforcing the scientific foundation behind Peptan’s holistic well-being benefits.
Alternatively, they can visit www.nextida.com and www.rousselot.com to learn more.
(1) Rousselot’s data, first clinical trial involving 16 healthy individuals that took 1 dose of Nextida GC before a meal. Reduced post-meal glucose spike by 43% (5-gram dose) and 40% (10-gram dose).
(2) Vleminckx, S., et al, Influence of collagen peptide supplementation on visible signs of skin and nail health and aging in an East Asian population: a double blind, randomized, placebo-controlled trial, Journal of Cosmetic Dermatology, 2024;00:1–9, https://doi.org/10.1111/jocd.16458.
(3) Virgilio, N., et al., Absorption of bioactive peptides following collagen hydrolysate intake: A randomized, double-blind crossover study in healthy individuals, Frontiers in Nutrition, 11, 1416643, 2024. https://pubmed.ncbi.nlm.nih.gov/39149544/
Rousselot makes no representation or warranty, whether expressed or implied, as to the accuracy, reliability, or completeness of the information, nor does it assume any legal liability, whether direct or indirect, for any information. Use of this information shall be at your discretion and risk. Nothing herein relieves you from carrying out your own suitability determinations and tests and from your obligation to comply with all applicable laws and regulations and to observe all third-party rights. This product is not intended to diagnose, treat, cure, or prevent any disease.
Cautionary Statements Regarding Forward-Looking Information
This release may contain “forward-looking statements,” which include information concerning the Company’s plans, objectives, goals and strategies and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied by the forward-looking statements contained in this release. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.